Vera Therapeutics, Inc. (VERA)

42,32 +2,81 (+7,11%) Al cierre: 04:00PM EDT

Vera Therapeutics, Inc.

8000 Marina Boulevard
Suite 120
Brisbane, CA 94005
United States
650 770 0077
https://veratx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 51

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Marshall W. Fordyce M.D.	Founder, President, CEO & Director	910,14k	N/A	1975
Mr. Sean P. Grant M.B.A.	Chief Financial Officer	642k	N/A	1985
Mr. Joseph R. Young M.B.A.	Senior VP of Finance & Chief Accounting Officer	N/A	N/A	1973
Mr. Julien E. Capers J.D.	VP & Head of Legal	N/A	N/A	N/A
Ms. Kelly Rauber	VP & Head of Human Resources	N/A	N/A	N/A
Mr. Tom Doan	Senior Vice President of Development Operations	N/A	N/A	1972
Ms. Lauren Frenz	Chief Business Officer	N/A	N/A	1985
Dr. Neeraj Pakala M.B.A., Ph.D.	Senior VP and Head of Product Development & Manufacturing	N/A	N/A	N/A
Dr. Kerry Cooper M.D.	Senior Vice President of Medical Affairs	N/A	N/A	N/A
Dr. Robert M. Brenner M.D.	Chief Medical Officer	N/A	N/A	1968

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Gobierno corporativo

El ISS Governance QualityScore de Vera Therapeutics, Inc., a día 29 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 8; Tablero: 5; Derechos de los accionistas: 8; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.